What is Ripple Science?
Founded in 2016, Ripple Science provides a sophisticated web-based software platform designed to optimize the clinical trial lifecycle. The company addresses the persistent challenges of patient recruitment and retention through a centralized dashboard that integrates campaign management, participant tracking, and task automation. By digitizing the administrative burden of clinical studies, Ripple Science enables project coordinators to maintain higher levels of engagement and data integrity throughout the research process. Its market position is defined by its ability to bridge the gap between complex clinical requirements and user-friendly digital management tools, effectively serving as a backbone for modern medical research operations.
How much funding has Ripple Science raised?
Ripple Science has raised a total of $4.3M across 2 funding rounds:
Angel/Seed
$1.8M
Other Financing Round
$2.5M
Angel/Seed (2019): $1.8M, investors not publicly disclosed
Other Financing Round (2020): $2.5M led by Red Cedar Ventures, SpringTime Ventures, Dundee VC, M25, Revolution’s Rise to the Rest Seed Fund, and Mercury Fund
Key Investors in Ripple Science
M25
A venture capital firm focused on investing in early-stage startups located in the Midwest, providing both capital and operational support to high-growth technology companies.
Mercury Fund
An early-stage venture capital firm that partners with entrepreneurs to build innovative software companies, with a specific focus on the B2B and enterprise technology sectors.
Red Cedar Ventures
A venture capital organization that specializes in supporting high-potential startups, often with a focus on university-affiliated or regional innovation ecosystems.
What's next for Ripple Science?
With the recent influx of capital, Ripple Science is well-positioned to scale its enterprise operations and enhance its product feature set. The strategic focus will likely center on deepening the integration capabilities of its platform to support larger, multi-site clinical trials, thereby increasing its value proposition for global CROs. As the company matures, it will likely prioritize the expansion of its sales and customer success teams to capture a larger share of the growing HealthTech market. The firm's ability to leverage this financing to improve patient outcomes through better trial management will be the primary metric for its long-term success in the competitive clinical research software landscape.
See full Ripple Science company page
